Literature DB >> 28965229

Treatment of Blepharospasm/Hemifacial Spasm.

Kemar E Green1, David Rastall2, Eric Eggenberger3.   

Abstract

OPINION STATEMENT: The treatment of both hemifacial spasm (HFS) and blepharospasm (BEB) requires making the appropriate clinical diagnosis. Advance imaging and electrophysiologic studies are useful; however, one's clinical suspicion is paramount. The purpose of this review is to summarize current and emerging therapies for both entities. Botulinum toxin (BTX) remains the first-line therapy to treat both conditions. If chemodenervation has failed, surgery may be considered. Due to the risks associated with surgery, the benefits of this option must be carefully weighed. Better surgical outcomes are possible when procedures are performed at tertiary centers with experienced surgeons and advanced imaging techniques. Microvascular decompression is an efficacious method to treat HFS, and myectomy is an option for medication-refractory BEB; the risks of the latter may outweigh any meaningful clinical benefits. Oral agents only provide short-term relief and can cause several unwanted effects; they are reserved for patients who cannot receive BTX and/or surgery. Transcranial magnetic stimulation has gained some traction in the treatment of BEB and may provide safer non-invasive options for refractory patients in the future.

Entities:  

Keywords:  Blepharospasm (BEB); Botulinum toxin; Dystonia; Facial nerve; Hemifacial spasm (HFS); Involuntary movement; Microvascular decompression (MVD); Myectomy

Year:  2017        PMID: 28965229     DOI: 10.1007/s11940-017-0475-0

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  115 in total

1.  Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm.

Authors:  Katalin Bihari
Journal:  Curr Med Res Opin       Date:  2005-03       Impact factor: 2.580

2.  Primary hypertension and neurovascular compression: a meta-analysis of magnetic resonance imaging studies.

Authors:  Hieronymus D Boogaarts; Tomas Menovsky; Joost de Vries; André L M Verbeek; Jacques W Lenders; J André Grotenhuis
Journal:  J Neurosurg       Date:  2011-09-16       Impact factor: 5.115

3.  A Survey of Current Blepharospasm Treatment Patterns Among Oculoplastic Surgeons.

Authors:  Talmage J Broadbent; Ralph E Wesley; Louise A Mawn
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2016 Jan-Feb       Impact factor: 1.746

4.  Therapeutic trials in Meige syndrome.

Authors:  S M Gollomp; S Fahn; R E Burke; A Reches; J Ilson
Journal:  Adv Neurol       Date:  1983

5.  Long-term efficacy of local doxorubicin chemomyectomy in patients with blepharospasm and hemifacial spasm.

Authors:  J D Wirtschafter; L K McLoon
Journal:  Ophthalmology       Date:  1998-02       Impact factor: 12.079

6.  The potential value of the disappearance of the lateral spread response during microvascular decompression for predicting the clinical outcome of hemifacial spasms: a prospective study.

Authors:  Chang-Hyun Kim; Doo-Sik Kong; Jeong Ah Lee
Journal:  Neurosurgery       Date:  2010-12       Impact factor: 4.654

7.  Hemifacial spasm: clinical findings and treatment.

Authors:  A Wang; J Jankovic
Journal:  Muscle Nerve       Date:  1998-12       Impact factor: 3.217

8.  Idiopathic hemifacial spasm responsive to zonisamide: a case report.

Authors:  Antonio Siniscalchi; Luca Gallelli; Caterina Palleria; Giovambattista De Sarro
Journal:  Clin Neuropharmacol       Date:  2009 Jul-Aug       Impact factor: 1.592

9.  A Dynamic Circuit Hypothesis for the Pathogenesis of Blepharospasm.

Authors:  David A Peterson; Terrence J Sejnowski
Journal:  Front Comput Neurosci       Date:  2017-03-07       Impact factor: 2.380

10.  Oculostapedial synkinesis.

Authors:  H P Schwarze; B E Hirsch; P C Johnson
Journal:  Otolaryngol Head Neck Surg       Date:  1995-12       Impact factor: 5.591

View more
  10 in total

Review 1.  Treatment of Depression with Botulinum Toxin.

Authors:  Marc Axel Wollmer; Michelle Magid; Tillmann H C Kruger; Eric Finzi
Journal:  Toxins (Basel)       Date:  2022-05-31       Impact factor: 5.075

2.  Electroacupuncture on Hemifacial Spasm and Temporomandibular Joint Pain Co-Morbidity: A Case Report.

Authors:  Jian-Peng Huang; Zhan-Mou Liang; Qi-Wen Zou; Jie Zhan; Wen-Ting Li; Sheng Li; Kai Li; Wen-Bin Fu; Jian-Hua Liu
Journal:  Front Neurol       Date:  2022-06-28       Impact factor: 4.086

Review 3.  Factors Related to Hemifacial Spasm Recurrence in Patients Undergoing Microvascular Decompression-A Systematic Review and Meta-Analysis.

Authors:  Grazia Menna; Marco Battistelli; Alessandro Rapisarda; Alessandro Izzo; Manuela D'Ercole; Alessandro Olivi; Nicola Montano
Journal:  Brain Sci       Date:  2022-04-29

Review 4.  Treatment of Visual Disorders in Parkinson Disease.

Authors:  Joseph Savitt; Michaela Mathews
Journal:  Curr Treat Options Neurol       Date:  2018-06-23       Impact factor: 3.598

5.  The outcome of microvascular decompression for hemifacial spasm: a systematic review and meta-analysis.

Authors:  Jianguo Li; Liang Lyu; Cheng Chen; Senlin Yin; Shu Jiang; Peizhi Zhou
Journal:  Neurosurg Rev       Date:  2022-01-20       Impact factor: 3.042

6.  How I do it: The Neuro-Ophthalmological Assessment in Parkinson's Disease.

Authors:  Carlijn D J M Borm; Katarzyna Smilowska; Nienke M de Vries; Bastiaan R Bloem; Thomas Theelen
Journal:  J Parkinsons Dis       Date:  2019       Impact factor: 5.568

7.  Postmarketing safety surveillance data reveals protective effects of botulinum toxin injections against incident anxiety.

Authors:  M Axel Wollmer; Tigran Makunts; Tillmann H C Krüger; Ruben Abagyan
Journal:  Sci Rep       Date:  2021-12-21       Impact factor: 4.379

8.  Postmarketing safety surveillance data reveals antidepressant effects of botulinum toxin across various indications and injection sites.

Authors:  Tigran Makunts; Marc Axel Wollmer; Ruben Abagyan
Journal:  Sci Rep       Date:  2020-07-30       Impact factor: 4.379

Review 9.  Management of Visual Dysfunction in Patients with Parkinson's Disease.

Authors:  Joseph Savitt; Rachid Aouchiche
Journal:  J Parkinsons Dis       Date:  2020       Impact factor: 5.568

Review 10.  Therapeutic Applications of Botulinum Neurotoxin for Autonomic Symptoms in Parkinson's Disease: An Updated Review.

Authors:  Steven D Mitchell; Christos Sidiropoulos
Journal:  Toxins (Basel)       Date:  2021-03-19       Impact factor: 4.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.